Objective To assess the clinical efficacy and adverse effect of pemetrexed-based chemotherapy as first-line treatment in elderly patients with advanced non-squamous non-small-cell lung cancer (NSCLC).Methods A total of 40 elderly patients with advanced non-squamous NSCLC confirmed by pathology were retrospective analyzed in the study,who received pemetrexed plus cisplatin (group A,n =18) or pemetrexed plus carboplatin (group B,n =22) as the first-line treatment.RECIST was used to assess the efficacy of the treatment and NCI-CTC AE version was used to describe adverse events.Results In the 40 patients,no one received complete response (CR),17 patients showed partial response (PR),16 had stable disease (SD),7 had progress disease (PD),the objective response rate (ORR) was 42.5 ％ (17/40) and the disease control rate (DCR) was 82.5 ％ (33/40).The median progression-free survival (PFS) time was 5.3 months.1 year suvival rate was 63.2 ％ (24/38).In further subgroup analyses,the ORR,DCR,PFS and 1 year suvival rate in group A were higher than those in group B,but they had no statistically significant difference (P ＞ 0.05).The drug-related adverse events were myelosuppression,gastrointestinal response,most of which were grade 1 to 2.Conclusion Pemetrexed combined with cisplatin or carboplatin may be recommended as first-line chemotherapy for elderly patients with advanced non-squamous NSCLC because of its safety and efficacy.

Objective To value the clinical efficacy and toxicity of S-1 compared to gemcitabine combined with S-1 in treatment of patients with advanced pancreatic cancer.Methods From January 2011 to December 2013,the data of 46 patients with advanced pancreatic cancer were analyzed retrospectively,including 24 patients receiving S-1 alone (group A) and 22 patients who received gemcitabine combined with S-1 (group B).The results were evaluated by objective response rate (ORR),disease control rate (DCR),survival time and safety.Results In group A the ORR was 20.8 ％ (5/24),DCR was 66.7 ％ (16/24),median progression-free survival was 4.8 months,median overall survival was 9.6 months,and 1 year survival was 12.5 ％.In group B the ORR was 27.3 ％ (6/22),DCR was 72.7 ％ (16/22),median progression-free survival was 5.9 months,median overall survival was 10.3 months,and 1 year survival was 22.7 ％.There was no significant difference between the two groups (P ＞ 0.05).The incidence rates of leukopenia,neutropenia and thrombopenia in group A were significantly lower than those in group B (P ＜ 0.05).Conclusion S-1 alone and gemcitabine combined with S-1 have similar effects in the treatment of advanced pancreatic cancer,but the toxicity of S-1 is mild and tolerable.

Objective To evaluate the association between CYP1A1 polymorphism and colorectal cancer risk.Methods PubMed,Embase and Web of Science databases were searched using the search terms as ‘Cytochrome P4501Al’,‘CYP1A1’,‘polymorphism’ and ‘colorectal cancer’.A meta-analysis was performed by STATA 10.0 software to assess the data included.Results By using 6768 cases and 7973 controls from 15 studies,significantly elevated colorectal cancer risks were associated with CYP1A1 2454A＞G in the following models (G vs A:pooled OR =1.19,95 ％ CI =1.03-1.37; GG vs AA:OR =1.40,95 ％ CI =1.12-1.75; GG vs AG+AA:OR =1.43,95 ％ CI =1.15-1.78).Conclusion CYP1A1 2454A＞G may cause an increased risk of colorectal cancer.

Objective To evaluate the clinical effects and safety of paclitaxel liposome or gemcitabine combined with cisplatin in elderly patients with advanced lung squamous cell cancer. Methods A total of 52 elderly patients with advanced lung squamous cell cancer in Kunshan First People's Hospital from January 2012 to October 2016 who received paclitaxel liposome with cisplatin (n=24) or gemcitabine with cisplatin(n = 28) were analyzed retrospectively. The patients received at least 2 cycles of chemotherapy, 2-6 cycles in total. CT was rechecked every 2 cycles. The clinical effects and adverse reactions were evaluated by National Cancer Institute Response Evaluation Criteria in Solid Tumors (NCI RECIST) and NCI Common Terminology Criteria for Adverse Events (NCI CTCAE). Results The objective response rate (ORR) and the disease control rate(DCR)in paclitaxel liposome group and in gemcitabine group had a lot in common [ORR:29.2 %(7/24)vs.32.1 %(9/28),χ2=0.054,P =0.817;DCR:70.8 %(17/24)vs.71.4 %(20/28),χ2=0.002,P =0.962]. The median progression-free survival(PFS) time in gemcitabine group was longer than that in paclitaxel liposome group (5.7 months vs. 5.4 months, χ2= 0.466, P = 0.495). One-year survival rate in gemcitabine group (37.0 %) was higher than that in paclitaxel liposome group (34.8 %) and there was no statistically significant difference (χ 2= 0.027, P = 0.869). However, hematologic adverse reactions in paclitaxel liposome group were lower than those in gemcitabine group (P< 0.05). Conclusion The effect of paclitaxel liposomes combined with cisplatin for treatment of elderly patients with advanced lung squamous cell carcinoma is not inferior to gemcitabine combined with cisplatin, which has less adverse reactions and may be recommended as the first-line chemotherapy for the patients.